PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug
Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
Approximately 10% to 15% of lung cancer patients have never smoked and have developed the disease due to genetic alterations.